↓ Skip to main content

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

Overview of attention for article published in Journal for Immunotherapy of Cancer, March 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#9 of 342)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news
58 news outlets

Citations

dimensions_citation
51 Dimensions

Readers on

mendeley
250 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials
Published in
Journal for Immunotherapy of Cancer, March 2016
DOI 10.1186/s40425-016-0118-0
Pubmed ID
Authors

Holbrook E. Kohrt, Paul C. Tumeh, Don Benson, Nina Bhardwaj, Joshua Brody, Silvia Formenti, Bernard A. Fox, Jerome Galon, Carl H. June, Michael Kalos, Ilan Kirsch, Thomas Kleen, Guido Kroemer, Lewis Lanier, Ron Levy, H. Kim Lyerly, Holden Maecker, Aurelien Marabelle, Jos Melenhorst, Jeffrey Miller, Ignacio Melero, Kunle Odunsi, Karolina Palucka, George Peoples, Antoni Ribas, Harlan Robins, William Robinson, Tito Serafini, Paul Sondel, Eric Vivier, Jeff Weber, Jedd Wolchok, Laurence Zitvogel, Mary L. Disis, Martin A. Cheever

Abstract

The efficacy of PD-1/PD-L1 targeted therapies in addition to anti-CTLA-4 solidifies immunotherapy as a modality to add to the anticancer arsenal. Despite raising the bar of clinical efficacy, immunologically targeted agents raise new challenges to conventional drug development paradigms by highlighting the limited relevance of assessing standard pharmacokinetics (PK) and pharmacodynamics (PD). Specifically, systemic and intratumoral immune effects have not consistently correlated with standard relationships between systemic dose, toxicity, and efficacy for cytotoxic therapies. Hence, PK and PD paradigms remain inadequate to guide the selection of doses and schedules, both starting and recommended Phase 2 for immunotherapies. The promise of harnessing the immune response against cancer must also be considered in light of unique and potentially serious toxicities. Refining immune endpoints to better inform clinical trial design represents a high priority challenge. The Cancer Immunotherapy Trials Network investigators review the immunodynamic effects of specific classes of immunotherapeutic agents to focus immune assessment modalities and sites, both systemic and importantly intratumoral, which are critical to the success of the rapidly growing field of immuno-oncology.

Mendeley readers

The data shown below were compiled from readership statistics for 250 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 1%
France 1 <1%
United Kingdom 1 <1%
India 1 <1%
Spain 1 <1%
Belgium 1 <1%
Unknown 242 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 78 31%
Student > Ph. D. Student 38 15%
Other 32 13%
Student > Bachelor 19 8%
Student > Master 13 5%
Other 37 15%
Unknown 33 13%
Readers by discipline Count As %
Medicine and Dentistry 53 21%
Biochemistry, Genetics and Molecular Biology 46 18%
Immunology and Microbiology 40 16%
Agricultural and Biological Sciences 34 14%
Pharmacology, Toxicology and Pharmaceutical Science 13 5%
Other 24 10%
Unknown 40 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 456. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 November 2016.
All research outputs
#10,953
of 8,614,521 outputs
Outputs from Journal for Immunotherapy of Cancer
#9
of 342 outputs
Outputs of similar age
#901
of 280,157 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#2
of 10 outputs
Altmetric has tracked 8,614,521 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 342 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.8. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 280,157 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 8 of them.